Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00103181 · ClinicalTrials.gov registry record · NA

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

A NA study of Breast Cancer, sponsored by NSABP Foundation.

Completed
Registry status
NA
Development phase
4,216
Enrollment target
20
Study locations

NCT00103181 is a NA study of Breast Cancer that has completed, run by NSABP Foundation. The registered enrollment target is 4,216 participants, above the 2,800-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (51% higher). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00103181, a NA study of Breast Cancer, has completed, sponsored by NSABP Foundation.

COMPLETED
Registry status
NA
Development phase
4,216 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill any tumor cells that remain after surgery. It is not yet known whether whole breast radiation therapy is more effective than partial breast radiation therapy in treating breast cancer. PURPOSE: This randomized phase III trial is studying whole breast radiation therapy to see how well it works compared to partial breast radiation therapy in treating women who have undergone surgery for ductal carcinoma in situ or stage I or stage II breast cancer.

Conditions Studied

Interventions

  • RADIATION brachytherapy
  • RADIATION whole breast irradiation
  • RADIATION 3-dimensional conformal accelerated partial breast irradiation
  • RADIATION MammoSite or other single-entry intracavitary device

Study Locations (20)

California

  • Auburn Radiation Oncology - Auburn
  • Alta Bates Summit Comprehensive Cancer Center - Berkeley
  • Peninsula Medical Center - Burlingame
  • Radiation Oncology Centers - Cameron Park - Cameron Park
  • Mercy Cancer Center at Mercy San Juan Medical Center - Carmichael
  • Enloe Cancer Center at Enloe Medical Center - Chico
  • Cancer Care Center at John Muir Health - Concord Campus - Concord
  • City of Hope Comprehensive Cancer Center - Duarte
  • North Bay Cancer Center - Fairfield
  • California Cancer Center - Woodward Park Office - Fresno
  • Kaiser Permanente Medical Center - Hayward - Hayward
  • Rebecca and John Moores UCSD Cancer Center - La Jolla
  • Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
  • Community Hospital of the Monterey Peninsula Comprehensive Cancer Center - Monterey

Arizona

  • Arizona Center for Cancer Care - Peoria - Peoria
  • Arizona Oncology Services Foundation - Phoenix
  • Arizona Breast Cancer Specialists - Scottsdale
  • Mayo Clinic Scottsdale - Scottsdale

Alabama

  • UAB Comprehensive Cancer Center - Birmingham

Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 4,216 participants
Start Date 2005-03
Est. Completion 2018-08
Phase NA

Sponsor

NSABP Foundation

44 total trials

What the Registry Record Tells You About NCT00103181

The ClinicalTrials.gov registry entry for NCT00103181 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4,216 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,800-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (51% higher). The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which brachytherapy is the first listed.

NCT00103181 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.

Frequently Asked Questions

What is clinical trial NCT00103181 about?

NCT00103181 is a clinical study titled "Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill any tumor cells that remain after surgery. It is not yet known whether whole breast radiation therapy is more effective than partial breast radiation therapy in treating brea...

What is the current status of trial NCT00103181?

This trial is currently completed. It is a NA study. The enrollment target is 4,216 participants. The study started on 2005-03. Estimated completion is 2018-08.

What conditions does trial NCT00103181 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00103181?

The interventions under investigation include: brachytherapy (RADIATION), whole breast irradiation (RADIATION), 3-dimensional conformal accelerated partial breast irradiation (RADIATION), MammoSite or other single-entry intracavitary device (RADIATION).

Who is sponsoring clinical trial NCT00103181?

This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00103181 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.